Providers

A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.

At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.

At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.

For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.

Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.

At ASN Kidney Week 2026, experts said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.

At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.

Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.

On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.

Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.

The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.

Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.

MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.

NCCN survey finds universal, persistent generic drug shortages; coping tactics stretch teams as looming tariffs threaten more supply disruptions.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

The action comes after an advisory panel recommended against approval, saying evidence from the did not support a “clinically meaningful benefit."

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk.

Nearly 1 in 3 women aged 21 to 29 years and 1 in 7 aged 30 to 65 years had never been screened for cervical cancer by 2023.

There are significant, and uneven, knowledge gaps among physicians treating patients with mantle cell lymphoma and chronic lymphocytic leukemia across countries and settings, a survey finds.

Orbital rhabdomyosarcoma survival held steady despite less-intensive chemo and radiation, according to 25-year data.

AI-driven platform boosts screening capacity 41%, cuts manual review by 75% across Ochsner's 47 hospitals and 370 clinics.